Global Neuroprotective Drugs Market Insights, Research, Forecast to 2025

Published On: Aug 2019

Format: PDF

Publisher: QY Research

Pages: 116

Report ID: 348259

Neuroprotective Drugs consist of medications that can be used to protect or preserve the neuronal cells of the brain from degeneration, stress, and injury, which can impair cognitive functions. 
The global Neuroprotective Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Neuroprotective Drugs market based on company, product type, end user and key regions.

This report studies the global market size of Neuroprotective Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Neuroprotective Drugs in these regions.
This research report categorizes the global Neuroprotective Drugs market by top players/brands, region, type and end user. This report also studies the global Neuroprotective Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Genervon Biopharmaceuticals (Canada)
NeuroVive Pharmaceutical (Sweden)
Ceregene (USA)
BHRPharma (Thailand)
Neuren Pharmaceuticals (Australia)
Allon therapeutics (Canada)
Bionure Inc. (USA)

Market size by Product
Cholinesterase inhibitors
Anti-inflammatory
Others
Market size by End User
Alzheimer's disease
Parkinson's disease
Others

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Neuroprotective Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Neuroprotective Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Neuroprotective Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Neuroprotective Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Neuroprotective Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Neuroprotective Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Study Coverage
1.1 Neuroprotective Drugs Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Neuroprotective Drugs Market Size Growth Rate by Product
1.4.2 Cholinesterase inhibitors
1.4.3 Anti-inflammatory
1.4.4 Others
1.5 Market by End User
1.5.1 Global Neuroprotective Drugs Market Size Growth Rate by End User
1.5.2 Alzheimer's disease
1.5.3 Parkinson's disease
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Neuroprotective Drugs Market Size
2.1.1 Global Neuroprotective Drugs Revenue 2014-2025
2.1.2 Global Neuroprotective Drugs Sales 2014-2025
2.2 Neuroprotective Drugs Growth Rate by Regions
2.2.1 Global Neuroprotective Drugs Sales by Regions
2.2.2 Global Neuroprotective Drugs Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 Neuroprotective Drugs Sales by Manufacturers
3.1.1 Neuroprotective Drugs Sales by Manufacturers
3.1.2 Neuroprotective Drugs Sales Market Share by Manufacturers
3.1.3 Global Neuroprotective Drugs Market Concentration Ratio (CR5 and HHI)
3.2 Neuroprotective Drugs Revenue by Manufacturers
3.2.1 Neuroprotective Drugs Revenue by Manufacturers (2014-2019)
3.2.2 Neuroprotective Drugs Revenue Share by Manufacturers (2014-2019)
3.3 Neuroprotective Drugs Price by Manufacturers
3.4 Neuroprotective Drugs Manufacturing Base Distribution, Product Types
3.4.1 Neuroprotective Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Neuroprotective Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Neuroprotective Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product
4.1 Global Neuroprotective Drugs Sales by Product
4.2 Global Neuroprotective Drugs Revenue by Product
4.3 Neuroprotective Drugs Price by Product

5 Breakdown Data by End User
5.1 Overview
5.2 Global Neuroprotective Drugs Breakdown Data by End User

6 North America
6.1 North America Neuroprotective Drugs by Countries
6.1.1 North America Neuroprotective Drugs Sales by Countries
6.1.2 North America Neuroprotective Drugs Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Neuroprotective Drugs by Product
6.3 North America Neuroprotective Drugs by End User

7 Europe
7.1 Europe Neuroprotective Drugs by Countries
7.1.1 Europe Neuroprotective Drugs Sales by Countries
7.1.2 Europe Neuroprotective Drugs Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Neuroprotective Drugs by Product
7.3 Europe Neuroprotective Drugs by End User

8 Asia Pacific
8.1 Asia Pacific Neuroprotective Drugs by Countries
8.1.1 Asia Pacific Neuroprotective Drugs Sales by Countries
8.1.2 Asia Pacific Neuroprotective Drugs Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Neuroprotective Drugs by Product
8.3 Asia Pacific Neuroprotective Drugs by End User

9 Central & South America
9.1 Central & South America Neuroprotective Drugs by Countries
9.1.1 Central & South America Neuroprotective Drugs Sales by Countries
9.1.2 Central & South America Neuroprotective Drugs Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Neuroprotective Drugs by Product
9.3 Central & South America Neuroprotective Drugs by End User

10 Middle East and Africa
10.1 Middle East and Africa Neuroprotective Drugs by Countries
10.1.1 Middle East and Africa Neuroprotective Drugs Sales by Countries
10.1.2 Middle East and Africa Neuroprotective Drugs Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Neuroprotective Drugs by Product
10.3 Middle East and Africa Neuroprotective Drugs by End User

11 Company Profiles
11.1 Genervon Biopharmaceuticals (Canada)
11.1.1 Genervon Biopharmaceuticals (Canada) Company Details
11.1.2 Company Business Overview
11.1.3 Genervon Biopharmaceuticals (Canada) Neuroprotective Drugs Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Genervon Biopharmaceuticals (Canada) Neuroprotective Drugs Products Offered
11.1.5 Genervon Biopharmaceuticals (Canada) Recent Development
11.2 NeuroVive Pharmaceutical (Sweden)
11.2.1 NeuroVive Pharmaceutical (Sweden) Company Details
11.2.2 Company Business Overview
11.2.3 NeuroVive Pharmaceutical (Sweden) Neuroprotective Drugs Sales, Revenue and Gross Margin (2014-2019)
11.2.4 NeuroVive Pharmaceutical (Sweden) Neuroprotective Drugs Products Offered
11.2.5 NeuroVive Pharmaceutical (Sweden) Recent Development
11.3 Ceregene (USA)
11.3.1 Ceregene (USA) Company Details
11.3.2 Company Business Overview
11.3.3 Ceregene (USA) Neuroprotective Drugs Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Ceregene (USA) Neuroprotective Drugs Products Offered
11.3.5 Ceregene (USA) Recent Development
11.4 BHRPharma (Thailand)
11.4.1 BHRPharma (Thailand) Company Details
11.4.2 Company Business Overview
11.4.3 BHRPharma (Thailand) Neuroprotective Drugs Sales, Revenue and Gross Margin (2014-2019)
11.4.4 BHRPharma (Thailand) Neuroprotective Drugs Products Offered
11.4.5 BHRPharma (Thailand) Recent Development
11.5 Neuren Pharmaceuticals (Australia)
11.5.1 Neuren Pharmaceuticals (Australia) Company Details
11.5.2 Company Business Overview
11.5.3 Neuren Pharmaceuticals (Australia) Neuroprotective Drugs Sales, Revenue and Gross Margin (2014-2019)
11.5.4 Neuren Pharmaceuticals (Australia) Neuroprotective Drugs Products Offered
11.5.5 Neuren Pharmaceuticals (Australia) Recent Development
11.6 Allon therapeutics (Canada)
11.6.1 Allon therapeutics (Canada) Company Details
11.6.2 Company Business Overview
11.6.3 Allon therapeutics (Canada) Neuroprotective Drugs Sales, Revenue and Gross Margin (2014-2019)
11.6.4 Allon therapeutics (Canada) Neuroprotective Drugs Products Offered
11.6.5 Allon therapeutics (Canada) Recent Development
11.7 Bionure Inc. (USA)
11.7.1 Bionure Inc. (USA) Company Details
11.7.2 Company Business Overview
11.7.3 Bionure Inc. (USA) Neuroprotective Drugs Sales, Revenue and Gross Margin (2014-2019)
11.7.4 Bionure Inc. (USA) Neuroprotective Drugs Products Offered
11.7.5 Bionure Inc. (USA) Recent Development

12 Future Forecast
12.1 Neuroprotective Drugs Market Forecast by Regions
12.1.1 Global Neuroprotective Drugs Sales Forecast by Regions 2019-2025
12.1.2 Global Neuroprotective Drugs Revenue Forecast by Regions 2019-2025
12.2 Neuroprotective Drugs Market Forecast by Product
12.2.1 Global Neuroprotective Drugs Sales Forecast by Product 2019-2025
12.2.2 Global Neuroprotective Drugs Revenue Forecast by Product 2019-2025
12.3 Neuroprotective Drugs Market Forecast by End User
12.4 North America Neuroprotective Drugs Forecast
12.5 Europe Neuroprotective Drugs Forecast
12.6 Asia Pacific Neuroprotective Drugs Forecast
12.7 Central & South America Neuroprotective Drugs Forecast
12.8 Middle East and Africa Neuroprotective Drugs Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Neuroprotective Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer